AGENDA
May 17, 2021
Session
HOUR ONE
9:00 AM – 10:00 AM EDT
WELCOME – Dr. Wafaa M. El-Sadr
SURVIVING SARS-COV2: LESSONS FROM 40+ YEARS OF HIV RESEARCH – Dr. Myron S. Cohen
HPTN: SCIENTIFIC AIMS FOR 2021 AND BEYOND – Dr. Wafaa M. El-Sadr
QUESTIONS & ANSWERS
HOUR TWO
10:00 AM – 11:00 AM EDT
MULTIPURPOSE PREVENTION TECHNOLOGIES FOR HIV PREVENTION: THE VISION, THE APPROACHES, AND THE CHALLENGES – Dr. Julie Pulerwitz and Dr. Lisa Haddad
CABOTEGRAVIR ROUNDTABLE DISCUSSION: PAST, PRESENT AND FUTURE – Moderated by Dr. Nirupama Sista
– Dr. Raphael J. Landovitz (HPTN 083)
– Dr. Sinead Delany-Moretlwe (HPTN 084)
– Dr. Sybil Hosek (HPTN 083-01/HPTN 084-01)
QUESTIONS & ANSWERS
LABORATORY CENTER
HOUR THREE
11:00 AM – 12:00 PM EDT
INTRODUCTION – LABORATORY CENTER PLENARY – Dr. Mark Marzinke
HPTN 083: HIV VIROLOGY AND DRUG RESISTANCE IN THE SETTING OF CAB LA PREP – Dr. Susan Eshleman
HIV PREVENTION AND THE VAGINAL MICROBIOME – Dr. Betsy Herold
SOURCE AND RECIPIENT CHARACTERISTICS OF HIV TRANSMISSION PAIRS IDENTIFIED IN THE HPTN 071 PHYLOGENETICS PROJECT – Dr. Matthew Hall
QUESTIONS & ANSWERS
May 19, 2021
Session
HOUR ONE9:00 AM – 10:00 AM EDT
WELCOME – Dr. Myron S. Cohen
NIAID PRIORITIES IN HIV/AIDS RESEARCH – Dr. Anthony S. Fauci
PREP SCALE-UP, SUCCESS AND CHALLENGES – Dr. Rachel Baggaley
QUESTIONS & ANSWERS
HOUR TWO
10:00 AM – 11:00 AM EDT
HPTN 094: A PERSON CENTERED, PUBLIC HEALTH APPROACH TO ADDRESS HIV AND THE U.S. OPIOID CRISES – Dr. Steven Shoptaw
HPTN 096: INTEGRATING MULTI-LEVEL STRATEGIES TO REDUCE HIV TRANSMISSION AMONG BLACK MSM IN THE SOUTHERN U.S.– Dr. LaRon Nelson
QUESTIONS & ANSWERS
WARD CATES SPIRIT AWARD
HPTN SCHOLARS
HOUR THREE11:00 AM – 12:00 PM EDT
INTRODUCTION – HPTN SCHOLARS PLENARY – Dr. David Serwadda
CLASSES OF SEXUAL IDENTITY, HOMOPHOBIA, AND SEXUAL RISK AMONG BLACK SEXUAL MINORITIES IN HPTN 061 – Dr. Rodman Turpin
AN EXAMINATION OF PERCEIVED AUTONOMY SUPPORT, CARE COORDINATION QUALITY, AND PREP DISCONTINUATION AMONG BLACK MSM IN THREE U.S. CITIES: HPTN 073 – Dr. Raquel Ramos
HIGHER COLORECTAL TISSUE INFECTIVITY IN HIV SERONEGATIVE CISGENDER WOMEN COMPARED TO MSM BOTH WITH & WITHOUT ORAL ANTIRETROVIRAL (ARV) PREP REGIMENS IN HPTN 069 STUDY – Dr. Rogers Sekabira
FACTORS ASSOCIATED WITH DAILY AND NON-DAILY SEX-RELATED PREP ADHERENCE AMONG WOMEN IN CAPE TOWN IN THE HPTN 067/ADAPT STUDY – Elzette Rousseau
SEXUAL RISK PROFILES AMONG BLACK SEXUAL MINORITY MEN: IMPLICATIONS FOR TARGETED PREP MESSAGING: HPTN 073 – Dr. Derek Dangerfield II
IDENTIFYING PREDICTIVE FACTORS FOR CONDOM USE IN MSM AND TGW IN SUB-SAHARAN AFRICA: RESULTS FROM HPTN 075 – Dr. Anita Marais
QUESTIONS & ANSWERS
May 21, 2021
Session
HOUR ONE
9:00 AM – 10:00 AM EDT
WELCOME – Dr. Wafaa M. El-Sadr
HPTN 091: LESSONS LEARNED INCORPORATING LIVED EXPERIENCES TO STRENGTHEN RESEARCH DESIGN – Nora Howell and Mia Ryan Porter
CDC PRIORITIES IN HIV RESEARCH AND PREVENTION– Dr. Rochelle P. Walensky
QUESTIONS & ANSWERS
STATISTICAL AND DATA MANAGEMENT CENTER
HOUR TWO
10:00 AM – 11:00 AM EDT
INTRODUCTION – STRATEGIES FOR FUTURE HIV PREVENTION TRIAL DESIGN – Dr. Deborah Donnell
USING CROSS SECTIONAL RECENCY ASSAYS TO ASSESS PREVENTION EFFICACY: FUTURE TRIAL DESIGN AND SAMPLE SIZE CONSIDERATIONS – Dr. Fei Gao
WHAT IS A WIN? DEFINING EFFICACY GOALS IN A TRIAL DESIGNED WITH A PLACEBO COUNTERFACTUAL – Dr. Jim Hughes
ESTIMATING THE EFFICACY OF LONG-ACTING PREP WITH A MODEL-BASED COUNTERFACTUAL PLACEBO – Dr. Mia Moore
ESTIMATING THE IMPACT OF PREP REGIMENS CONTAINING LONG-ACTING INJECTABLE CABOTEGRAVIR OR DAILY ORAL TDF/FTC AMONG MEN WHO HAVE SEX WITH MEN IN THE UNITED STATES: MATHEMATICAL MODELLING FOR HPTN 083 – Dr. Kate Mitchell
QUESTIONS & ANSWERS
HOUR THREE
11:00 AM – 12:00 PM EDT
NETWORK AWARDS – Dr. Quarraisha Abdool Karim
CLOSING REMARKS – Dr. Myron S. Cohen and Dr. Wafaa M. El-Sadr